Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug220 | Adenovirus Type-5 Vectored COVID-19 Vaccine Wiki | 0.71 |
| drug214 | Ad5-nCoV Wiki | 0.71 |
| drug1795 | Hydroxychloroquine Sulfate Wiki | 0.41 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There are 2 clinical trials
This is an exploratory study to evaluate the efficacy of hydroxychloroquine (400 mg BID on D1 and 400 mg/day on D2 to D5) and azithromycin (500 mg/ 5 days) to treat moderate to severe COVID-19 pneumonia.
Description: Evaluation of change from baseline. Kaplan-meier method will be used.
Measure: Evolution of acute respiratory syndrome, oxygen saturation hemodynamic stability Time: 28 daysDescription: Evaluation of change in viral load
Measure: Viral load Time: Day 6Description: Time for normalization of body temperature, respiratory rate and cough relief
Measure: Change in Clinical Condition Time: 28 daysDescription: Time to wean off oxygen supplementation and / or invasive / non-invasive ventilatory support;
Measure: Evolution of Acute Respiratory Syndrome Time: 28 daysDescription: Time to be discharged from hospital
Measure: Hospital discharge Time: 28 daysDescription: Evaluation of change in acute respiratory syndrome
Measure: Rate of mortality within 28-days Time: 28 daysThis is an exploratory study to evaluate the efficacy of hydroxychloroquine (400 mg BID on D1 and 400 mg/day on D2 to D7) and azithromycin (500 mg/ 5 days) to treat mild ambulatory COVID-19 patients.
Description: Ordinal scale (7 points ordinal scale that measures illness severity over time)
Measure: Change in Clinical Condition Time: 28 daysDescription: Number of patients that needed to be hospitalized
Measure: Hospitalization Time: 28 daysDescription: Time for normalization of body temperature
Measure: Change in Clinical Condition Time: 28 daysDescription: Time for normalization of of respiratory rate
Measure: Change in Clinical Condition Time: 28 daysDescription: Time for cough relief
Measure: Change in Clinical Condition Time: 28 daysDescription: Evaluation of change in acute respiratory syndrome
Measure: Rate of mortality within 28-days Time: 28 daysDescription: Subgroup analysis by comorbidities
Measure: Change in Clinical Condition related to comorbidity Time: 28 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports